Capital Research Global Investors Ultragenyx Pharmaceutical Inc. Transaction History

Capital Research Global Investors

$463 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$62.2 - $84.4 $26.4 Million - $35.9 Million	-425,160 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $216 Million - $258 Million	-2,936,632 Reduced 87.35%	425,160 $35.8 Million
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $94.1 Million - $124 Million	-1,207,013 Reduced 26.42%	3,361,792 $303 Million
Q2 2021 Aug 16, 2021	SELL	$92.19 - $115.71 $259 Million - $325 Million	-2,805,068 Reduced 38.04%	4,568,805 $436 Million
Q1 2021 May 14, 2021	BUY	$106.9 - $167.73 $12 Million - $18.8 Million	111,972 Added 1.54%	7,373,873 $840 Million
Q4 2020 Feb 12, 2021	BUY	$84.4 - $177.39 $40.3 Million - $84.8 Million	477,833 Added 7.04%	7,261,901 $1.01 Billion
Q3 2020 Nov 13, 2020	BUY	$72.98 - $90.0 $328,628 - $405,270	4,503 Added 0.07%	6,784,068 $558 Million
Q2 2020 Aug 14, 2020	BUY	$46.91 - $78.22 $9.64 Million - $16.1 Million	205,605 Added 3.13%	6,779,565 $530 Million
Q1 2020 May 15, 2020	BUY	$33.8 - $62.9 $7.14 Million - $13.3 Million	211,265 Added 3.32%	6,573,960 $292 Million
Q4 2019 Feb 18, 2020	BUY	$36.08 - $45.83 $198,945 - $252,706	5,514 Added 0.09%	6,362,695 $272 Million
Q3 2019 Nov 14, 2019	BUY	$42.5 - $63.11 $2,337 - $3,471	55 Added 0.0%	6,357,181 $272 Million
Q2 2019 Aug 14, 2019	BUY	$54.93 - $74.36 $93,051 - $125,965	1,694 Added 0.03%	6,357,126 $404 Million
Q1 2019 May 15, 2019	BUY	$39.87 - $69.36 $19.9 Million - $34.6 Million	499,277 Added 8.53%	6,355,432 $441 Million
Q4 2018 Feb 14, 2019	BUY	$38.89 - $77.3 $661 - $1,314	17 Added 0.0%	5,856,155 $255 Million
Q3 2018 Nov 14, 2018	BUY	$71.81 - $90.15 $7.22 Million - $9.07 Million	100,575 Added 1.75%	5,856,138 $447 Million
Q2 2018 Aug 14, 2018	SELL	$48.54 - $85.31 $7.71 Million - $13.6 Million	-158,884 Reduced 2.69%	5,755,563 $442 Million
Q1 2018 May 15, 2018	BUY	$44.33 - $58.52 $41.2 Million - $54.4 Million	929,442 Added 18.64%	5,914,447 $302 Million
Q4 2017 Feb 14, 2018	BUY	$43.54 - $57.32 $39 Million - $51.3 Million	895,266 Added 21.89%	4,985,005 $231 Million
Q3 2017 Nov 14, 2017	BUY	$49.79 - $66.32 $204 Million - $271 Million	4,089,739	4,089,739 $218 Million

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.5M

Call Options Held

520K

Put Options Held

406K

Vanguard Group Inc Valley Forge, PA

9.95M
Shares

$446 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.6M
Shares

$251 Million
0.01% of portfolio
Sands Capital Management, LLC Arlington, VA

5.12M
Shares

$230 Million
0.91% of portfolio
Wellington Management Group LLP Boston, MA

4.17M
Shares

$187 Million
0.04% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.07M
Shares

$138 Million
0.02% of portfolio

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital Research Global Investors with notifications on news.

Account